The findings of anti-ETAR and anti-ETBR autoantibodies are driving factors skewing subjects toward an SLE diagnosis and highlight the potential utility of these biomarkers as a biosignature for SLE-associated vascular dysfunction and subsequent inflammation. The gene discussed is EDNRB; the disease is systemic lupus erythematosus.